Expression of somatostatin receptors in splanchnic blood vessels of normal and cirrhotic rats

Liver International

Volumn 27, Issue 6, 2007, Pages 825-831

  Reynaert, Hendrik ^a,b   van Rossen, Elke ^a   Uyama, Naoki ^a   Chatterjee, Nirjhar ^c   Kumar, Ujendra ^d   Urbain, Daniel ^b   Geerts, Albert ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UCB   (Belgium)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cirrhosis; Portal hypertension; Portal vein; Somatostatin receptor; TAA

Indexed keywords

MESSENGER RNA; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; THIOACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; MESENTERIC ARTERY; NONHUMAN; PORTAL VEIN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; AORTA; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MEMBRANE PROTEINS; MESENTERIC ARTERY, SUPERIOR; PORTAL VEIN; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIOACETAMIDE;

EID: 34447319638     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01503.x     Document Type: Article

References (24)

1. Gupta TK, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Baillieres Clin Gastroenterol 1997; 11: 203-19.
2. Lebrec D. Pharmacological treatment of portal hypertension: Present and future. J Hepatol 1998; 28: 896-907.
3. D'amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis 1999; 19: 475-505.
4. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981; 80: 518-25.
5. Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 2003; 18: 375-86.
6. Reynaert H, Vaeyens F, Qin H, et al. Somatostatin suppresses endothelin-1-induced rat hepatic stellate cell contraction via somatostatin receptor subtype 1. Gastroenterology 2001; 121: 915-30.
7. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2001; 120: 975-83.
8. Huang HC, Lee FY, Chan CC, et al. Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats. J Hepatol 2002; 36: 163-8.
9. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120: 161-9.
10. Primignani M, Carpinelli L, Vazzoler MC, et al. Sort-term effect of octreotide on intraoesophageal pressure: A double-blind placebo-controlled study. Eur J Gastroenterol Hepatol 1994; 6: 1027-31.
11. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation. Hepatology 1995; 22: 106-11.
12. Villanueva C, Ortiz J, Minana J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121: 110-7.
13. Curtis SB, Chen JC, Winkelaar G, et al. Effect of endothelial and adventitial injury on somatostatin receptor expression. Surgery 2000; 127: 577-83.
14. Khare S, Kumar U, Sasi R, et al. Differential regulation of somatostatin receptors types 1-5 in rat aorta after angioplasty. FASEB J 1999; 13: 387-94.
15. Hori N, Okanoue T, Sawa Y, et al. Hemodynamic characterization in experimental liver cirrhosis induced by thioacetamide administration. Dig Dis Sci 1993; 38: 2195-202.
16. Okuyama H, Shimahara Y, Kawada N, et al. Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor β. J Biol Chem 2001; 276: 28274-80.
17. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999; 48: 77-85.
18. Kumar U, Laird D, Srikant CB, et al. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: Quantitative analysis by double-label immunofluorescence confocal microscopy. Endocrinology 1997; 138: 4473-6.
19. Laleman W, Vander EI, Zeegers M, et al. A stable model of cirrhotic portal hypertension in the rat: Thioacetamide revisited. Eur J Clin Invest 2006; 36: 242-9.
20. Malmqvist U. Effects of long-term portal hypertension on structure, active force and content of contractile and structural proteins in smooth muscle of the rat portal vein. Acta Physiol Scand 1994; 150: 171-9.
21. Curtis SB, Hewett J, Yakubovitz S, et al. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 2000; 278: H1815-22.
22. Patel YC, Greenwood M, Panetta R, et al. Molecular biology of somatostatin receptor subtypes. Metabolism 1996; 45: 31-8.
23. Goulis J, Burroughs AK. Role of vasoactive drugs in the treatment of bleeding oesophageal varices. Digestion 1999; 60 (Suppl. 3): 25-34.
24. Van Heule E, Geerts A, Reynaert H, et al. Intravital microscopy study of the influence of somatostatin on liver microcirculation in an experimental mouse model of cirrhosis. Hepatology 2005; 42 (Suppl. 1): A419.